DOCSLIB.ORG

Cetuximab Combined with Chemotherapy Is Beneficial for Patients with Advanced Non-Small Cell Lung Cancer After EGFR-Tyrosine Kinase Inhibitors Failure

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cetuximab Combined with Chemotherapy Is Beneficial for Patients with Advanced Non-Small Cell Lung Cancer After EGFR-Tyrosine Kinase Inhibitors Failure Int J Clin Exp Med 2015;8(9):16140-16148 www.ijcem.com /ISSN:1940-5901/IJCEM0012202 Original Article Cetuximab combined with chemotherapy is beneficial for patients with advanced non-small cell lung cancer after EGFR-tyrosine kinase inhibitors failure Feng Zhang1*, You Yu2*, Lina Xing1, Min Chen1 1Department of Radiation Oncology, The Second Affiliated Hospital, Harbin Medical University, Harbin, China; 2Department of Pediatric Surgery, The First Affiliated Hospital, Harbin Medical University, Harbin, China.* Equal contributors. Received July 1, 2015; Accepted August 27, 2015; Epub September 15, 2015; Published September 30, 2015 Abstract: To determine if cetuximab combined with chemotherapy is beneficial for patients with advanced NSCLC af- ter failure of first-line chemotherapy and EGFR-tyrosine kinase inhibitors (TKI). Twenty patients were treated with ce- tuximab in combination with pemetrexed, and 14 patients were treated with cetuximab in combination with docetax- el. Short-term response rates and long-term survival after salvage therapy were evaluated. Partial response (PR) occurred in 4 patients, stable disease (SD) occurred in 13 patients, and progressive disease (PD) occurred in 17 patients. No patient achieved a complete response (CR). The objective response rate (ORR) was 11.8% (4/34) and the disease control rate (DCR) was 50.0% (17/34). The disease progression rate (DPR) was 50% (17/34). Further analyses showed that the DCR was significantly higher in patients treated with EGFR-TKI for ≥6 months compared to patients treated with EGFR-TKI for <6 months (P=0.031). The median follow-up time was 5.5 months. The median progression-free survival (PFS) was 4.1 months. PFS was significantly longer in patients treated with EGFR-TKI for ≥ 6 months compared to those treated <6 months with EGFR-TKI (5.9 vs. 3.0 months; P=0.004). In general, however, patients tolerated this therapy well and there were no therapy-related deaths. As a salvage therapy, cetuximab combined with chemotherapy is indeed beneficial for patients with advanced NSCLC after first-line chemotherapy and subsequent EGFR-TKI treatment failure. In particular, this salvage regimen is beneficial for patients who were treated with EGFR-TKI for ≥6 months, and is well tolerated in these patients. Keywords: Lung cancer, cetuximab, chemotherapy, salvage therapy, EGFR Introduction cellular processes, including promotion of cell proliferation, angiogenesis induction, and apop- Non-small cell lung cancer (NSCLC) accounts tosis inhibition [12-14]. for 80%-85% of newly diagnosed lung cancers. Approximately 65% of NSCLC patients are in EGFR tyrosine kinase inhibitors (EGFR-TKI) are advanced stages at the time of diagnosis, and a group of inhibitors that target EGFR tyrosine therefore, the opportunity for surgical resection kinase activity. Gefitinib and erlotinib are two is lost [1-3]. Epidermal growth factor receptor widely used EGFR-TKIs. These inhibitors are (EGFR)-targeted therapy has been widely used selective EGFR tyrosine kinase inhibitors and to treated lung cancer and has achieved mea- have specific effects on cancer cell growth, surable effects in these patients [4-6]. EGFR is metastasis, and angiogenesis by blocking EGFR a 170 kDa transmembrane protein that is wide- tyrosine kinase phosphorylation [15-18]. A vari- ly expressed in many malignancies, including ety of cancer treatment guidelines have recom- lung, colon, and breast cancers [7-11]. EGFR mended EGFR-TKI therapy as first-line, second- signaling is one of the most studied pathways line, or third-line agents to treat NSCLC and to in cancer progression. Phosphorylation of EGFR maintain chemotherapy. Most advanced NSCLC leads to activation of its downstream target patients receive EGFR-TKI therapy at certain genes. These genes are involved in a variety of stages during the disease process. Acquired Cetuximab in TKI-resistant advanced NSCLC resistance to EGFR-TKI therapy is common dur- conducted in accordance with the guidelines of ing the treatment course [19-21]. Subsequent Clinical Research Ethics Board at our hospital. treatment in patients with advanced NSCLC Written informed consent was obtained from all after acquiring EGFR-TIK-resistance is a signifi- patients before the inclusion in the study. Our cant concern. hospital approved this study. Currently, antibody therapy combined with che- Study design motherapy is an important alternative treat- ment strategy for cancer patients. It is becom- All patients received salvage therapy. Salvage ing more widely accepted, particularly as a sal- treatment consisted of cetuximab combined vage therapy for those patients resisting first- with either pemetrexed (regimen A) or docetax- line chemotherapy. Cetuximab (Erbitux) is the el (regimen B). An initial loading dose of cetux- first approved monoclonal antibody (IgG1) imab at 400 mg/m2 was administered over 2 against EGFR. It binds to the EGFR ligand and hours. Cetuximab was intravenously injected blocks downstream pathways of EGFR signal weekly at a dose of 250 mg/m2. The delivery transduction, thereby inhibiting cancer cell pro- speed did not exceed 5 ml/min. In addition to liferation and growth [22-24]. The combination cetuximab, 20 patients (58.8%) in regimen A of cetuximab and chemotherapeutic agents to were concurrently given 500 mg/m2 peme- treat stage I-II NSCLC after failed EGFR-TKI trexed on day 1, continuing once every 3 weeks. treatment has been reported, and cetuximab Fourteen patients (41.2%) in regimen B were can sensitize early stage NSCLC to subsequent concurrently given 75 mg/m2 docetaxel on day chemotherapy [7, 25]. However, whether a simi- 1, continuing once every 3 weeks. Standard lar outcome occurs in EGFR-TKI-resistant ad- premedications consisted of 0.4 g cimetidine, vanced NSCLC is not yet known. 5 mg diphenhydramine, and 5 mg dexametha- sone. Patients participated in the study until The primary objective of this study was to deter- the disease progressed, unacceptable toxicity, mine if salvage therapy based on combining death, or withdrawal of consent. Two patients cetuximab with chemotherapeutic agents can experienced disease progression after one improve the therapeutic efficacy in patients treatment cycle. The remaining 32 patients with advanced NSCLC after resistance to initial were treated for at least two cycles. The medi- first-line chemotherapy and subsequent EGFR- an number of treatment cycles was three cycles TKI treatments. For this purpose, we conducted (1-6 cycles). a retrospective study in 34 patients with ad- vanced NSCLC whose first-line platinum-based Patient baseline information chemotherapy and EGFR-TKI failed. Baseline clinical and pathological characteris- Materials and methods tics of patients were collected, including sex, age, pathological classification, tumor stage, Eligibility criteria smoking status, PS score, first-line chemother- apy, and duration of EGFR-TKI treatment. Ad- For inclusion in this study, all patients satisfi- ditionally, physical examinations, weight mea- ed the following criteria: 1) Pathologically con- surements, hematology and chemistry tests, firmed advanced NSCLC according to the 2009 urinalyses, electrocardiograms, and Eastern International Association for the Study of Lung Cooperative Oncology Group (ECOG) perfor- Cancer staging system [26]; 2) Refractory to mance status were assessed at baseline. first-line standard chemotherapy containing Imaging studies (computed tomography or platinum and resistant to subsequent erlotinib magnetic resonance imaging) were performed or gefitinib treatment; 3) An Eastern Cooperative at baseline and every 6 weeks or longer. Oncology Group (ECOG) performance status score of ≤2 [27]; 4) Predicted survival time was Treatment assessments longer than three months; and (5) Normal bone marrow, liver, and kidney function. A total of 34 The lung cancer remission rate (RR) was as- patients was collected from March 2007 to sessed according to a modified version of the May 2013. This study and all treatments were Response Evaluation Criteria in Solid Tumors 16141 Int J Clin Exp Med 2015;8(9):16140-16148 Cetuximab in TKI-resistant advanced NSCLC Table 1. Baseline characteristics of the study Cancer Institute (NCI) Common Terminology population Criteria for Adverse Events version 3.0]. Parameters No. of patients % Statistical analyses Sex Male 23 67.6 SPSS 15.0 statistical software was used to Female 11 32.4 analyze all data in this study. P<0.05 is consid- PS score ered statistically significant. The participating 0-1 22 64.7 investigators determined PFS. Adverse events 2 12 35.3 were assessed according to the NCI Common Pathological diagnosis Terminology Criteria for Adverse Events (CTCAE) version 3.0. Only events that were reported as Adenocarcinoma 24 70.6 possibly, probably, or definitely related to treat- Squamous cell carcinoma 6 17.6 ment protocols were included in these analy- Unknown 4 11.8 ses. Progression-free survival was estimated Smoking status using the Kaplan-Meier product-limit method Smoker 14 41.2 [29]. Non-smoker 20 58.8 EGFR-TKI agent Results Gefitinib 19 55.9 Patient characteristics Erlotinib 15 44.1 EGFR-TKI preference A total of 34 patients participated in this retro- Second-line 18 52 spective study. The majority of patients were Above second-line 16 48 male (67.6%), were treated with EGFR-TKI for EGFR-TKI duration less than 6 months (64.7%), had PS scores of ≥6 Months 12 35.3 0-1 (64.7%), and had histological diagnoses of <6 Months 22 64.7 adenocarcinoma (70.6%). The percentage of Note: EGFR-TKI, epidermal growth factor receptor tyro- patients who smoked (either currently or in the sine kinase inhibitor. past) was similar to patients who did not smoke or never smoked (41.2% vs. 58.8%). EGFR-TKI was given as second-line treatment in 52% of 1.0 guidelines [28], and were divided into com- patients, and as first-line treatment in 48% of plete remission (complete response, CR), par- patients. The majority of patients (55.9%) re- tial remission (partial response, PR), stable ceived gefitinib treatment, whereas 44.1% of (stable disease, SD), and progression (progres- patients received erlotinib treatment.
Load more

Recommended publications
  • I4X-JE-JFCM an Open-Label, Multicenter, Phase 1B/2 Study To
    Protocol (e) I4X-JE-JFCM An Open-label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC) NCT01763788 Approval Date: 12-Jun-2016 I4X-JE-JFCM(e) Clinical Protocol Page 1 1. Protocol I4X-JE-JFCM(e) An Open-label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC) Confidential Information The information contained in this protocol is confidential and is intended for the use of clinical investigators. It is the property of Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical investigation of Necitumumab (IMC-11F8; LY3012211), unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its subsidiaries. Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries. Necitumumab (IMC-11F8; LY3012211) Gemcitabine (LY188011) This is a Phase 1b/2 study in the first-line treatment of patients with advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC).
    [Show full text]
  • Erbitux® (Cetuximab)
    Erbitux® (cetuximab) (Intravenous) -E- Document Number: MODA-0494 Last Review Date: 06/01/2021 Date of Origin: 09/03/2019 Dates Reviewed: 09/2019, 01/2020, 04/2020, 07/2020, 10/2020, 01/2021, 04/2021, 06/2021 I. Length of Authorization 1 Coverage will be provided for six months and may be renewed unless otherwise specified. • SCCHN in combination with radiation therapy: Coverage will be provided for the duration of radiation therapy (6-7 weeks). II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: Weekly Every two weeks Erbitux 100 mg/50 mL solution for injection 1 vial every 7 days 1 vial every 14 days 3 vials every 7 days Erbitux 200 mg/100 mL solution for injection 6 vials every 14 days (5 vials for first dose only) B. Max Units (per dose and over time) [HCPCS Unit]: Weekly Every two weeks − Load: 100 billable units x 1 dose 120 billable units every 14 days − Maintenance Dose: 60 billable units every 7 days III. Initial Approval Criteria 1 Coverage is provided in the following conditions: • Patient is at least 18 years of age; AND Colorectal Cancer (CRC) † ‡ 1,2,12,13,17,19,2e,5e-8e,10e-12e,15e • Patient is both KRAS and NRAS mutation negative (wild-type) as determined by FDA- approved or CLIA-compliant test*; AND • Will not be used as part of an adjuvant treatment regimen; AND • Patient has not been previously treated with cetuximab or panitumumab; AND • Will not be used in combination with an anti-VEGF agent (e.g., bevacizumab, ramucirumab); AND Moda Health Plan, Inc.
    [Show full text]
  • Monoclonal Antibodies
    MONOCLONAL ANTIBODIES ALEMTUZUMAB ® (CAMPATH 1H ) I. MECHANISM OF ACTION Antibody-dependent lysis of leukemic cells following cell surface binding. Alemtuzumab is a recombinant DNA-derived humanized monoclonal antibody that is directed against surface glycoprotein CD52. CD52 is expressed on the surface of normal and malignant B and T lymphocytes, NK cells, monocytes, macrophages, a subpopulation of granulocytes, and tissues of the male reproductive system (CD 52 is not expressed on erythrocytes or hematopoietic stem cells). The alemtuzumab antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine monoclonal antibody (campath 1G). II. PHARMACOKINETICS Cmax and AUC show dose proportionality over increasing dose ranges. The overall average half-life is 12 days. Peak and trough levels of Campath rise during the first weeks of Campath therapy, and approach steady state by week 6. The rise in serum Campath concentration corresponds with the reduction in malignant lymphocytes. III. DOSAGE AND ADMINISTRATION Campath can be administered intravenously or subcutaneously. Intravenous: Alemtuzumab therapy should be initiated at a dose of 3 mg administered as a 2-hour IV infusion daily. When the 3 mg dose is tolerated (i.e., ≤ Grade 2 infusion related side effects), the daily dose should be escalated to 10mg and continued until tolerated (i.e., ≤ Grade 2 infusion related side effects). When the 10 mg dose is tolerated, the maintenance dose of 30 mg may be initiated. The maintenance dose of alemtuzumab is 30 mg/day administered three times a week on alternate days (i.e. Monday, Wednesday, and Friday), for up to 12 weeks.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,345,661 B2 Adler Et Al
    USOO9345661 B2 (12) United States Patent (10) Patent No.: US 9,345,661 B2 Adler et al. (45) Date of Patent: May 24, 2016 (54) SUBCUTANEOUSANTI-HER2 ANTIBODY FOREIGN PATENT DOCUMENTS FORMULATIONS AND USES THEREOF CL 2756-2005 10/2005 CL 561-2011 3, 2011 (75) Inventors: Michael Adler, Riehen (CH); Ulla CL 269-2012 1, 2012 Grauschopf, Riehen (CH): CN 101163717 4/2008 Hanns-Christian Mahler, Basel (CH): CN 101370525 2, 2009 Oliver Boris Stauch, Freiburg (DE) EP O590058 B1 11, 2003 EP 1516628 B1 3, 2005 (73) Assignee: Genentech, Inc., South San Francisco, EP 1603541 11, 2009 JP 2007-533631 11, 2007 CA (US) JP 2008-5075.20 3, 2008 JP 2008-528638 T 2008 (*) Notice: Subject to any disclaimer, the term of this JP 2009-504142 2, 2009 patent is extended or adjusted under 35 JP 2009/055343 4/2009 U.S.C. 154(b) by 0 days. KR 2007-0068385 6, 2007 WO 93.21319 A1 10, 1993 WO 94/OO136 A1 1, 1994 (21) Appl. No.: 12/804,703 WO 97.048O1 2, 1997 WO 98.22136 5, 1998 (22) Filed: Jul. 27, 2010 WO 99.57134 11, 1999 WO 01.00245 A2 1, 2001 (65) Prior Publication Data WO 2004/078140 9, 2004 WO 2005/023328 3, 2005 US 2011 FOO44977 A1 Feb. 24, 2011 WO 2005/037992 A2 4/2005 WO 2005,117986 12/2005 (30) Foreign Application Priority Data WO WO 2005,117986 A2 * 12/2005 WO 2006/044908 A2 4/2006 Jul. 31, 2009 (EP) ..................................... 0.9167025 WO 2006/09 1871 8, 2006 WO 2007 O24715 3, 2007 (51) Int.
    [Show full text]
  • Cyramza® (Ramucirumab)
    Cyramza® (ramucirumab) (Intravenous) -E- Document Number: MODA-0405 Last Review Date: 07/01/2021 Date of Origin: 09/03/2019 Dates Reviewed: 09/2019, 10/2019, 01/2020, 04/2020, 07/2020, 10/2020, 01/2021, 04/2021, 07/2021 I. Length of Authorization Coverage will be provided for 6 months and may be renewed. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: • Cyramza 100 mg/10 mL: 4 vials per 14 days • Cyramza 500 mg/50 mL: 2 vials per 14 days B. Max Units (per dose and over time) [HCPCS Unit]: Gastric, Gastroesophageal, HCC, and Colorectal Cancer: • 180 billable units every 14 days NSCLC: • 240 billable units every 14 days III. Initial Approval Criteria 1 Coverage is provided in the following conditions: • Patient is at least 18 years of age; AND Universal Criteria 1 • Patient does not have uncontrolled severe hypertension; AND • Patient must not have had a surgical procedure within the preceding 28 days or have a surgical wound that has not fully healed; AND Gastric, Esophageal, and Gastro-esophageal Junction Adenocarcinoma † Ф 1-3,5-7,14,17,2e,5e • Used as subsequent therapy after fluoropyrimidine- or platinum-containing chemotherapy; AND • Used as a single agent OR in combination with paclitaxel; AND o Used for one of the following: Moda Health Plan, Inc. Medical Necessity Criteria Page 1/27 Proprietary & Confidential © 2021 Magellan Health, Inc. – Patient has unresectable locally advanced, recurrent, or metastatic disease; OR – Used as palliative therapy for locoregional disease in patients who are not surgical candidates
    [Show full text]
  • EGFR and HER-2 Antagonists in Breast Cancer
    ANTICANCER RESEARCH 27: 1285-1294 (2007) Review EGFR and HER-2 Antagonists in Breast Cancer NORMA O’DONOVAN1 and JOHN CROWN1,2 1National Institute for Cellular Biotechnology, Dublin City University, Dublin 9; 2Department of Medical Oncology, St. Vincent’s University Hospital, Dublin 4, Ireland Abstract. Both HER-2 and EGFR are expressed in breast tumorigenesis was obtained using transgenic mice expressing cancer and are implicated in its development and progression. an activated form of the HER-2/neu oncogene in the The discovery of the association between HER-2 gene mammary epithelium, which resulted in rapid induction of amplification and poor prognosis in breast cancer led to the mammary tumours in 100% of female transgenic carriers (4). development of HER-2 targeted therapies. Trastuzumab, a Recent microarray analysis of breast tumours has monoclonal antibody to HER-2, has significantly improved the identified four distinct sub-types of tumours (5, 6). The sub- prognosis for HER-2-positive breast cancer patients. It is now types are classified as (i) luminal (further sub-divided into approved for the treatment of both HER-2-positive metastatic A and B) (ii) HER-2-positive/estrogen receptor (ER) - breast cancer and early stage HER-2-positive breast cancer. negative, (iii) normal-like and (iv) basal-like. The basal-like Recent results from trials of the dual HER-2 and EGFR sub-type lacks expression of ER, progesterone receptor tyrosine kinase inhibitor, lapatinib, also show very promising (PR) and HER-2, but expression of EGFR is more results in HER-2-positive breast cancer. A number of EGFR frequently observed in this sub-type.
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • Management of EGFR-Mutation Positive Metastatic Non-Small Cell Lung Cancer
    Management of EGFR-Mutation Positive Metastatic Non-Small Cell Lung Cancer Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center Rogerio Lilenbaum, MD Yale Cancer Center/Smilow Cancer Hospital EGFR Mutation in Advanced NSCLC: NCCN, Florida 2016 Rogerio Lilenbaum, MD Professor of Medicine Yale Cancer Center Chief Medical Officer Smilow Cancer Hospital Copyright 2016©, National Comprehensive Cancer Network®. All rights reserved. No part of this publication may be reproduced or transmitted in any other form or by any means, electronic or mechanical, without first obtaining written permission from NCCN®. Molecular Targeted Therapy in Cancer Personalized Medicine in Lung Cancer No known genotype 2004 ‐ 2005 2009 2013 Copyright 2016©, National Comprehensive Cancer Network®. All rights reserved. No part of this publication may be reproduced or transmitted in any other form or by any means, electronic or mechanical, without first obtaining written permission from NCCN®. Molecular Alterations in Lung Adenocarcinoma SURVIVAL driverNoTx driverTx noDriver 0.0 0.2 0.4 0.6 0.8 1.0 012345 YE A RS Note: Does not include ROS1 or RET Sholl LM et al, 2015; Johnson BE, et al. ASCO 2013 Tumor Profiling at Yale • Tier 1: Reflex testing using TaqMan platform –5 to 7 days • Tier 2: Oncomine Cancer Panel (143 genes and >40 translocations/fusions) on Ion Torrent – 2 weeks • Tier 3: Whole exome sequencing with future custom panels per organ system specification – 2-3 weeks Copyright 2016©, National Comprehensive Cancer Network®. All rights reserved. No part of this publication may be reproduced or transmitted in any other form or by any means, electronic or mechanical, without first obtaining written permission from NCCN®.
    [Show full text]
  • Second-Line FOLFIRI Plus Ramucirumab with Or Without Prior
    Cancer Chemotherapy and Pharmacology (2019) 84:307–313 https://doi.org/10.1007/s00280-019-03855-w ORIGINAL ARTICLE Second‑line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer Takeshi Suzuki1,2 · Eiji Shinozaki1 · Hiroki Osumi1 · Izuma Nakayama1 · Yumiko Ota1 · Takashi Ichimura1 · Mariko Ogura1 · Takeru Wakatsuki1 · Akira Ooki1 · Daisuke Takahari1 · Mitsukuni Suenaga1 · Keisho Chin1 · Kensei Yamaguchi1 Received: 13 February 2019 / Accepted: 2 May 2019 / Published online: 7 May 2019 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Purpose Few data of folinic acid, fuorouracil, and irinotecan (FOLFIRI) plus ramucirumab (RAM) obtained in bevacizumab- naïve patients in clinical trials or routine clinical practice are available. The purpose of this retrospective study was to report the results of FOLFIRI plus RAM treatment as second-line chemotherapy for metastatic colorectal cancer (mCRC). Methods Seventy-four patients with mCRC who received second-line FOLFIRI + RAM mCRC therapy were stratifed by previous frst-line therapy to groups that had (PB) or had not (NPB) been given bevacizumab. The overall survival (OS), progression-free survival (PFS), and objective response were evaluated. Results The overall median PFS was 6.2 months (95% CI 4.6–9.3) and median OS was 17.0 months (95% CI 11.6–NA). Median PFS was 8.0 months (95% CI 4.9–11.2) in NPB patients and 5.0 months (95% CI 3.1–7.3) in PB patients (hazard ratio = 0.72, 95% CI 0.40–1.30, p = 0.28). The response rates were 23% and 3% in NPB and PB patients, respectively.
    [Show full text]
  • Anti-EGFR Antibody 528 Binds to Domain III of EGFR at a Site
    www.nature.com/scientificreports OPEN Anti‑EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope Koki Makabe1, Takeshi Yokoyama2,3, Shiro Uehara2, Tomomi Uchikubo‑Kamo3, Mikako Shirouzu3, Kouki Kimura4, Kouhei Tsumoto5,6, Ryutaro Asano4, Yoshikazu Tanaka2 & Izumi Kumagai4* Antibodies have been widely used for cancer therapy owing to their ability to distinguish cancer cells by recognizing cancer‑specifc antigens. Epidermal growth factor receptor (EGFR) is a promising target for the cancer therapeutics, against which several antibody clones have been developed and brought into therapeutic use. Another antibody clone, 528, is an antagonistic anti‑EGFR antibody, which has been the focus of our antibody engineering studies to develop cancer drugs. In this study, we explored the interaction of 528 with the extracellular region of EGFR (sEGFR) via binding analyses and structural studies. Dot blotting experiments with heat treated sEGFR and surface plasmon resonance binding experiments revealed that 528 recognizes the tertiary structure of sEGFR and exhibits competitive binding to sEGFR with EGF and cetuximab. Single particle analysis of the sEGFR–528 Fab complex via electron microscopy clearly showed the binding of 528 to domain III of sEGFR, the domain to which EGF and cetuximab bind, explaining its antagonistic activity. Comparison between the two‑ dimensional class average and the cetuximab/sEGFR crystal structure revealed that 528 binds to a site that is shifted from, rather than identical to, the cetuximab epitope, and may exclude known drug‑ resistant EGFR mutations. Epidermal growth factor receptor (EGFR) is a member of the closely related family of ErbB transmembrane protein tyrosine kinase receptors.
    [Show full text]
  • Study Protocol C25002 Amendment 4, Eudract: 2011-001240-29
    Title: A Phase 1/2 Study of brentuximab vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma NCT Number: NCT01492088 Protocol Approve Date: 12 June 2014 Certain information within this protocol has been redacted (ie, specific content is masked irreversibly from view with a black/blue bar) to protect either personally identifiable information or company confidential information. This may include, but is not limited to, redaction of the following: Named persons or organizations associated with the study. Proprietary information, such as scales or coding systems, which are considered confidential information under prior agreements with license holder. • Other information as needed to protect confidentiality of Takeda or partners, personal information, or to otherwise protect the integrity of the clinical study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
    [Show full text]
  • HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
    cancers Review HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors Kimio Yonesaka Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi Osaka-Sayamashi, Osaka 589-8511, Japan; [email protected]; Tel.: +81-72-366-0221; Fax: +81-72-360-5000 Simple Summary: Epidermal growth factor receptor (EGFR) is one of the anticancer drug targets for certain malignancies including nonsmall cell lung cancer (NSCLC), colorectal cancer (CRC), and head and neck squamous cell carcinoma. However, the grave issue of drug resistance through diverse mechanisms persists. Since the discovery of aberrantly activated human epidermal growth factor receptor-2 (HER2) and HER3 mediating resistance to EGFR-inhibitors, intensive investigations on HER2- and HER3-targeting treatments have revealed their advantages and limitations. An innovative antibody-drug conjugate (ADC) technology, with a new linker-payload system, has provided a solution to overcome this resistance. HER2-targeting ADC trastuzumab deruxtecan or HER3-targeting ADC patritumab deruxtecan, using the same cleavable linker-payload system, demonstrated promising responsiveness in patients with HER2-positive CRC or EGFR-mutated NSCLC, respectively. The current manuscript presents an overview of the accumulated evidence on HER2- and HER3-targeting therapy and discussion on remaining issues for further improvement of treatments for cancers resistant to EGFR-inhibitors. Abstract: Epidermal growth factor receptor (EGFR) is one of the anticancer drug targets for certain Citation: Yonesaka, K. malignancies, including nonsmall cell lung cancer (NSCLC), colorectal cancer (CRC), and head HER2-/HER3-Targeting and neck squamous cell carcinoma. However, the grave issue of drug resistance through diverse Antibody—Drug Conjugates for mechanisms persists, including secondary EGFR-mutation and its downstream RAS/RAF mutation.
    [Show full text]